{"text": "new hope : 50 young people are diagnosed with ms each week . thousands of people with ms could benefit from the first pill to treat the disabling disease . the nhs rationing body has approved the drug fingolimod which can halve relapses compared with standard interferon injections . experts hoped the once-a-day pill will replace injections and hospital infusions for at least 5,000 sufferers a year . in its initial assessment , the national institute for health and clinical excellence -lrb- nice -rrb- said the drug was not value for money despite admitting it works . but after considering extra evidence on its effectiveness nice decided to give the go-ahead for use on the nhs . dr eli silber , a consultant neurologist who leads the ms service for south london based at king 's college hospital , and was involved in trials , said . ` we 've waited a long time for an effective oral treatment to offer patients who are continuing to relapse on first line injections . ` today 's decision increases treatment choice . because it is a highly effective oral agent it may change the way ms is managed in the uk forever . ` with more active forms of ms , we have a limited window of opportunity to make a difference to patients ' lives - many are young people who are raising families and starting their careers . ' i want to get appropriate patients onto this therapy as quickly as possible . ' ms is the most common disabling . neurological condition , affecting almost 100,000 britons - 50 young . people are diagnosed each week . it . involves damage to myelin , a protective sheath surrounding nerve fibres . of the central nervous system which means the body 's immune system . attacks itself . symptoms . range from mild , occasional illness involving numbness , muscle weakness . and eye problems to rapid and severe deterioration , resulting in . serious disability . on screen portrayal : actor martin sheen played president josiah bartlet in the west wing , who suffered physical disabilities due to ms . trial results in the new england journal of medicine last year showed fingolimod , also known as gilenya , cut relapse rates and progression of the disease . patients treated with fingolimod had a 50 per cent cut in disabling relapses compared with commonly used injections of beta interferon . the chances of progressing to a worse form of the disease were cut by about a third , without significant side effects . the new drug appears to dampen the immune response that causes nerve damage in multiple sclerosis . the # 19,000 annual cost of the drug compares with the # 21,000 annual cost of hospital infusions using tysabri , and manufacturer novartis has devised a patient access scheme that cuts the price . ms specialists say the drug could make overall savings for the nhs , because fewer patients would need hospital treatment costing # 3,000 a time after relapse and disability is lessened . the draft guidance from nice means it will be funded by the nhs in england and wales after final guidance is issued next month . the drug , made by novartis , was rejected for nhs use by the scottish medicines consortium -lrb- smc -rrb- . nick rijke , director of policy & research at the ms society , said : ` we are delighted ; this decision signifies a major step forward in the treatment of this devastating condition . ` gilenya has been found to be highly effective in trials and taking a daily tablet will come as welcome relief from frequent , often unpleasant , injections . ` making this new treatment available will increase patient choice for thousands of people with ms across england and wales , but we 're deeply disappointed by the smc 's decision in scotland - and urge them to reconsider . ' professor carole longson , director of the health technology evaluation centre at nice said : ` following new information provided during the consultation , the analyses show that for these people -lrb- with highly active ms -rrb- , treatment with fingolimod will be a cost effective option for the nhs , if novartis provides the drug at a discounted price , as proposed in its patient access scheme . '", "summary": " multiple sclerosis is most common disabling neurological condition , affecting almost 100,000 britons .   new drug approved from england and wales but not scotland . "}